Novavax Inc (NVAX)
Novavax Inc (NVAX) is a biotechnology company specializing in the development and commercialization of innovative vaccines to prevent serious infectious diseases. Founded in 1987, Novavax focuses on nanoparticle technology and adjuvants to create vaccines for influenza, RSV, COVID-19, and other diseases. The company aims to provide safe and effective immunization options through its advanced vaccine platforms.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2007 | $0.11 | 2007-12-13 | 2007-12-17 |
| November 30, 2007 | $0.11 | 2007-11-13 | 2007-11-15 |
| October 31, 2007 | $0.11 | 2007-10-11 | 2007-10-15 |
| September 28, 2007 | $0.11 | 2007-09-13 | 2007-09-17 |
| August 31, 2007 | $0.11 | 2007-08-13 | 2007-08-15 |
Dividends Summary
- Novavax Inc has issued 6 dividend payments over the past 0 years
- The most recent dividend was paid 6473 days ago, on December 31, 2007
- The highest dividend payed out to investors during this period was $0.10625 per share
- The average dividend paid during this period was $0.11 per share.
Company News
The FDA is seeking to lift privacy rules on COVID-19 vaccine data for pregnant women to reveal potential side effects, amid ongoing debates about vaccine safety and transparency led by health officials like FDA Commissioner Marty Makary.
The global vaccine adjuvants market is projected to grow from USD 3.83 billion in 2024 to USD 5.43 billion by 2032, with a 4.47% CAGR, driven by increasing vaccine efficacy demands and global immunization programs.
Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.
Moderna's COVID-19 vaccine demand has plunged, leading the company to lower its 2025 revenue guidance by $1 billion. This has caused Moderna's stock to decline by 20% this week. However, the company still has a strong cash position and a pipeline of promising new products that could drive future growth.
The article discusses the average brokerage recommendation (ABR) for Novavax (NVAX) stock, which suggests a 'Buy' rating. However, the article cautions that brokerage recommendations may not always be reliable indicators of a stock's future performance, and recommends using the Zacks Rank as a more effective tool for investment decisions.
